Protagonist Therapeutics (PTGX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

Strategic and financial outlook

• Transitioned to a commercial-stage company with Icotyde, partnered with J&J, and anticipates potential approval of Rusfertide in Q3, partnered with Takeda.

• Strong financial position with ample cash, incoming royalties, and milestones; no foreseeable need for equity raises.

• Considering a steady share buyback program, contingent on Rusfertide approval to solidify revenue projections.

• Focused on partnerships for large indications, while retaining full development for niche and rare disease markets.

• R&D pipeline is robust and de-risked, leveraging validated biology targets and peptide expertise.

Product and pipeline updates

• Icotyde launch is exceeding expectations, with rapid prescriber uptake and strong market share gains; peak sales projected at $10–15 billion.

• Icotyde is the only approved oral IL-23 receptor blocker, with ongoing phase III studies in additional indications (psoriatic arthritis, UC, Crohn's).

• Rusfertide's PDUFA date is in August; Takeda estimates peak sales of $1–2 billion, with favorable milestone and royalty economics for the company.

• PN-881, an oral IL-17 inhibitor, is advancing in clinical development, uniquely targeting both A and F isotypes.

• Obesity program focuses on differentiated oral peptides, with plans to partner before phase III due to market scale and cost considerations.

Commercial and market positioning

• Icotyde is positioned to capture market share from injectables and address unmet needs in the I&I space, with potential to expand beyond psoriasis.

• Rusfertide aims to replace outdated phlebotomy in PV, offering symptom improvement and broad utility across patient risk profiles.

• PN-881 leverages learnings from Icotyde development, with phase II design signaling data strength and partnership interest already high.

• Obesity portfolio includes both incretin and non-incretin approaches, aiming for broad pharma partnership appeal.

• Maintains flexibility to develop niche products independently while seeking partners for large-scale indications.